BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
CYTK upcoming catalysts
Cytokinetics: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 2 readout(s) and 2 FDA event(s). Subscribe to CYTK (.ics).
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|
| No upcoming PDUFA date or AdCom found. |
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|
| No trials in this window. |
FDA decision events, last 12 months
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|
| 2026-09 est. | P2 | Cytokinetics CYTK | NCT06793371 AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | recruiting | 60 |
| 2026-08-31 | P3 | Cytokinetics CYTK | NCT06081894 A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | active not recruiting | 500 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.